All Updates

All Updates

icon
Filter
Funding
Enveda Biosciences raises USD 51 million in oversubscribed Series B1 round
AI Drug Discovery
Apr 20, 2023
This week:
Funding
MeliBio receives strategic investment from Future Food Fund
Alternative Ingredients
Yesterday
Product updates
Catchfree launches microalgae-based shrimp alternative
Plant-based Meat
Yesterday
Product updates
AQUA Cultured Foods introduces fermentation-based raw tuna alternative
Plant-based Meat
Yesterday
Management news
SDI Element Logic rebrands as Element Logic
Logistics Tech
Yesterday
Geographic expansion
Wayve opens office and commences testing of automated driving features in US
Auto Tech
Yesterday
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
AI Drug Discovery

AI Drug Discovery

Apr 20, 2023

Enveda Biosciences raises USD 51 million in oversubscribed Series B1 round

Funding

  • AI biotechnology company Enveda Biosciences has raised USD 51 million in an oversubscribed Series B1 funding round, bringing the total Series B funds to USD 119 million (the previous Series A round closed in December 2022 ). The latest round was led by ​​Kinnevik, with participation from existing investors FPV, True Ventures, and Dimension, among others. 

  • The Colorado-based company develops novel therapeutics based on plants and nature chemistry to treat a variety of diseases including Wilson’s Disease, NASH, and Parkinson’s disease. Enveda’s proprietary platform, which is powered by machine learning and metabolomics, acts as a search engine to discover and identify novel drug candidates. 

  • The fresh funds will be directed toward advancing the company’s molecules into the clinic in 2023 and 2024.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.